Showing 9391-9400 of 21412 results for "".
Advancing ATTR-CM Identification: Early Findings from TRACE-AI
https://reachmd.com/programs/heart-matters/attr-cm-identification-trace-ai-findings/67275/Could multimodal AI help identify patients with transthyretin amyloid cardiomyopathy (ATTR-CM) who might otherwise go undiagnosed? Dr. Bruno Batinica, a Postdoctoral Associate at the Yale School of Medicine, joins us to share early findings from the TRACE-AI study, including AI-enabled model performRecognizing and Managing Chronic Hand Eczema as a Distinct Inflammatory Disease
https://reachmd.com/programs/dermconsult/recognizing-managing-chronic-hand-eczema-distinct-disease/56719/Chronic hand eczema can be difficult to characterize and manage. Subtypes may overlap, triggers can take time to identify, and different inflammatory pathways may be at play, all while patients continue to experience burdensome symptoms. Join Dr. Shelina Ramnarine and Dr. Firas George Hougeir as theTailoring Inflammatory Bowel Disease Care: Selection Criteria and Timing
https://reachmd.com/programs/gi-insights/tailoring-inflammatory-bowel-disease-care-selection-criteria-and-timing/35591/As the advanced treatment landscape for inflammatory bowel disease continues to expand, selecting the right therapies has become more complex, with efficacy, safety, patient preferences, disease phenotypes, and more as factors to consider. Learn how to effectively navigate these therapeutic optionsLiving Well with IBD: Proactive Health Maintenance Strategies
https://reachmd.com/programs/gi-insights/living-well-with-ibd-proactive-health-maintenance-strategies/18013/Join us as we explore how we can optimize the health of our patients with IBD using strategies that go beyond the treatment of symptoms and disease.Recognizing Pulmonary Hypertension in Interstitial Lung Disease
https://reachmd.com/programs/clinicians-roundtable/recognizing-ph-in-ild/54229/Pulmonary hypertension (PH) associated with interstitial lung disease (ILD) can be difficult to recognize, particularly because symptoms and signs of clinical deterioration often overlap with ILD progression. Join Dr. Jean Elwing as she explains the clinical clues that should raise suspicion. She'sIntegrating POCUS Findings with Clinical Context at the Bedside
https://reachmd.com/programs/clinicians-roundtable/pocus-findings-clinical-context-bedside/54232/Point-of-care ultrasound (POCUS) involves more than just image acquisition and interpretation; it requires immediate integration of ultrasound findings with the patient’s clinical presentation. Join Dr. Taro Minami as he discusses how clinicians can incorporate POCUS into bedside assessment and whyHighlights from VBS 2026: From Care Innovations to Clinician Wellness
https://reachmd.com/programs/eye-on-ocular-health/vbs-2026-innovations-clinician-wellness/56547/The 2026 Vit-Buckle Society (VBS) Annual Meeting featured candid case-based discussions on real-world complications and innovative approaches, as well as sessions dedicated to promoting physician wellness. Catch up on insights from this year's meeting with Dr. Akshay Thomas, a vitreoretinal surgeonImproving Colorectal Cancer Screening Adherence: Advantages of FIT
https://reachmd.com/programs/clinicians-roundtable/improving-colorectal-cancer-screening-adherence-advantages-of-fit/36703/For younger adults needing to get screened for colorectal cancer, fecal immunochemical testing (FIT) may help with initiation and adherence because of its speed, ease, and noninvasiveness. Hear Dr. Theodore Levin discuss FIT and its potential benefits, particularly in younger adults. Dr. Levin is aFriedreich’s Ataxia: Impact of Frataxin Loss
https://reachmd.com/programs/neurofrontiers/friedreichs-ataxia-impact-of-frataxin-loss/54670/Frataxin deficiency in Friedreich’s ataxia leads to cardiac and neurologic dysfunction, driven in part by oxidative stress and mitochondrial impairment. Join Dr. Arnie Koeppen as he discusses how these effects shape disease pathology and challenge traditional views of organ involvement. Dr. KoeppenIL-17A Inhibition and the Stress Response in Psoriasis
https://reachmd.com/programs/Audioabstracts/il-17a-inhibition-stress-response-psoriasis/39684/When prescribing secukinumab, we focus on IL-17A blockade to clear psoriatic plaques—but could this targeted therapy also influence the body’s stress system? Join Ryan Quigley as he walks through a 16-week clinical study exploring how IL-17A inhibition affects the hypothalamic–pituitary–adrenal axis